Overview

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn:

• If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver
• About the safety of efinopegdutide and how well people tolerate it

Eligibility

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH)
• Has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has history of a liver disease other than MASH, for example, Hepatitis B or C, drug-induced liver disease, or autoimmune liver disease
• Has history of type 1 diabetes
• Had a bariatric surgical procedure less than 5 years before entry into the study
• History of pancreatitis
• Major illnesses like recent (within 6 months of study entry) episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke